Literature DB >> 10469893

Mechanisms of resistance to the toxicity of cyclophosphamide.

M P Gamcsik1, M E Dolan, B S Andersson, D Murray.   

Abstract

Resistance to cyclophosphamide therapy continues to be a major reason for treatment failure. This chapter covers some of the mechanisms implicated in resistance to the toxic and mutagenic effects of cyclophosphamide therapy in the laboratory and clinic. Since resistance is likely to be the result of a number of interrelating factors, this chapter evaluates the contribution of both glutathione and DNA repair processes to cyclophosphamide resistance. Glutathione appears to be involved directly in the detoxification of cyclophosphamide and metabolites and may play a more indirect role in other processes. The ability of the cell to repair cyclophosphamide-induced DNA lesions, possibly through nucleotide excision repair or other processes, may be a key contributor to drug resistance. Interestingly, the presence of the repair enzyme, O6-alkylguanine-DNA alkyltransferase, long thought to be involved with resistance to methylating and chloroethylating agents, may also contribute to resistance to the cytotoxic and mutagenic effects of cyclophosphamide.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10469893

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  12 in total

1.  Unscheduled DNA synthesis: a functional assay for global genomic nucleotide excision repair.

Authors:  Crystal M Kelly; Jean J Latimer
Journal:  Methods Mol Biol       Date:  2005

Review 2.  Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.

Authors:  Claudia M Hattinger; Serena Vella; Elisa Tavanti; Marilù Fanelli; Piero Picci; Massimo Serra
Journal:  Pharmacogenomics       Date:  2016-11-24       Impact factor: 2.533

Review 3.  Roles of reactive oxygen species and antioxidants in ovarian toxicity.

Authors:  Patrick J Devine; Sally D Perreault; Ulrike Luderer
Journal:  Biol Reprod       Date:  2012-02-09       Impact factor: 4.285

4.  Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.

Authors:  Junji Hiraga; Tomohiro Kinoshita; Toshihito Ohno; Naoyoshi Mori; Haruhiko Ohashi; Shouko Fukami; Atsuhiko Noda; Atsushi Ichikawa; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-10       Impact factor: 2.490

Review 5.  Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease.

Authors:  Jing Liu; Jie Zhao; Liang Hu; Yuchun Cao; Bo Huang
Journal:  Cell Mol Immunol       Date:  2011-03-21       Impact factor: 11.530

6.  Unique tissue-specific level of DNA nucleotide excision repair in primary human mammary epithelial cultures.

Authors:  Jean J Latimer; Tariq Nazir; Lisa C Flowers; Michael J Forlenza; Kelly Beaudry-Rodgers; Crystal M Kelly; Julie A Conte; Kenneth Shestak; Amal Kanbour-Shakir; Stephen G Grant
Journal:  Exp Cell Res       Date:  2003-11-15       Impact factor: 3.905

Review 7.  Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.

Authors:  Navin Pinto; Susan M Ludeman; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2009-12       Impact factor: 2.533

8.  Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Authors:  Ryan J Hansen; Susan M Ludeman; Sari J Paikoff; Anthony E Pegg; M Eileen Dolan
Journal:  DNA Repair (Amst)       Date:  2007-05-07

9.  Unscheduled DNA synthesis: the clinical and functional assay for global genomic DNA nucleotide excision repair.

Authors:  Jean J Latimer; Crystal M Kelly
Journal:  Methods Mol Biol       Date:  2014

Review 10.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.